

The Power of Knowing

BGI SENTIS™ HPV Test

Introduction

Human papilloma virus (HPV) infection is associated with nearly all of cervical cancer cases (95%) worldwide[1]. Identification of HPV is an important tool for screening and prevention of carcinoma of the cervix. The BGI HPV Test combines self-sampling technology and genotyping assay to detect 14 “high-risk” types of HPV, including HPV -16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68and 3 “intermediate-risk” types of the virus, HPV -53, 73, 82.

In many parts of the world, HPV testing has replaced Pap smear test as the primary screening test for cervical cancer.

Advantages

Comprehensive Detection Technology

High-throughput sequencing technology

Outstanding Testing Performance

98.82% sensitivity and 99.14% specificity

Self-Sampling method

Convinient & Private & Storing-friendly

TAT:14 working days

Sample: Cervical Exfoliated Cells

Workflow

Sample requirement

Sample type	Storage media	Quantity & Quality	Storage & Shipment
Cervical exfoliated cells	FTA Card	Sample region turns to be while form purple.	Stored and shipped at room temperature, reaching BGI lab within 7 days.

Applicable Clinical Scenarios

Women who have had sexual intercourse.

Non-applicable Clinical Scenarios

Women who are pregnant.
Women who have had a total hysterectomy.
Women who have received pelvic radiation therapy.

[1] Kusakabe M, et al. Carcinogenesis and management of human papillomavirus-associated cervical cancer. Int J Clin Oncol. 2023 Aug;28(8):965-974

To learn how your research can benefit from BGI's extensive experience in genomics, visit www.bgi.com/global/, write to us via info@bgi.com or contact your local BGI representative.